APA (7th ed.) Citation

Taniki, N., Ojiro, K., Kasuga, R., Nakadai, Y., Tabuchi, T., Chu, P., . . . Jinzaki, M. (2026). Advantage of Scheduled Upfront Lenvatinib Administration Followed by Transarterial Chemoembolization Therapy Over Lenvatinib Monotherapy in Patients With Unresectable Intermediate‐Stage Hepatocellular Carcinoma: A Multicenter Cohort Study. Cancer Medicine, 15(1), 1. https://doi.org/10.1002/cam4.71503

Chicago Style (17th ed.) Citation

Taniki, Nobuhito, et al. "Advantage of Scheduled Upfront Lenvatinib Administration Followed by Transarterial Chemoembolization Therapy Over Lenvatinib Monotherapy in Patients With Unresectable Intermediate‐Stage Hepatocellular Carcinoma: A Multicenter Cohort Study." Cancer Medicine 15, no. 1 (2026): 1. https://doi.org/10.1002/cam4.71503.

MLA (9th ed.) Citation

Taniki, Nobuhito, et al. "Advantage of Scheduled Upfront Lenvatinib Administration Followed by Transarterial Chemoembolization Therapy Over Lenvatinib Monotherapy in Patients With Unresectable Intermediate‐Stage Hepatocellular Carcinoma: A Multicenter Cohort Study." Cancer Medicine, vol. 15, no. 1, 2026, p. 1, https://doi.org/10.1002/cam4.71503.